Dolores Grosso
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Thomas Jefferson University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Dolores Grosso as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:20 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03317899 · Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin LymphomaSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · completed · Non-Hodgkin's Lymphoma, Plasma Cell Myeloma · principal investigator
- Ph2NCT01982682 · Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical DonorSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · completed · Hematopoietic/Lymphoid Cancer · principal investigator
- Ph2NCT01871441 · Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic MalignanciesSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · terminated · Malignant Neoplasm · principal investigator
- Ph2NCT01760655 · Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic MalignanciesSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · completed · Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM · principal investigator
- N/ANCT01660347 · Donor Stem Cell Boost in Treating Patients With Low Blood Cells After Donor Stem Cell TransplantSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · withdrawn · Anemia, Hematopoietic/Lymphoid Cancer, Lymphopenia · principal investigator
- Ph2NCT01532635 · A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched RelativesSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · terminated · Hematologic Malignancy, Leukemia, Acute Lymphoblastic Leukemia · principal investigator
- Ph1/Ph2NCT01350258 · Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two StepsSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · terminated · Hematologic Malignancies, Acute Leukemia, Myelodysplastic Syndromes (MDS) Other Than RA or RARS Subtypes · principal investigator
- Ph2NCT01350245 · Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative DonorSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · completed · Acute Myeloid Leukemia, Myelodysplastic Syndromes, Biphenotypic Leukemia · principal investigator
- Ph2NCT01341301 · Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic MalignanciesSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · completed · Hematologic Malignancy · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:20 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:20 UTC. The ranking covers the 200 most relevant of 14 PubMed records, and a shared surname and initials can bring in a namesake. All 14 on PubMed
- Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).Br J Cancer · 2007155 citationsRCR 3.3
- How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial.Neurology · 2004101 citationsRCR 2.2
- 67 citationsRCR 1.8
- Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study.Biol Blood Marrow Transplant · 200453 citationsRCR 1.3
- A two-step approach to myeloablative haploidentical transplantation: low nonrelapse mortality and high survival confirmed in patients with earlier stage disease.Biol Blood Marrow Transplant · 201537 citationsRCR 1.3
- A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation.Biol Blood Marrow Transplant · 201622 citationsRCR 0.8
- Teleradiology for remote consultation using iPad improves the use of health system human resources for paediatric fractures: prospective controlled study in a tertiary care hospital in Italy.BMC Health Serv Res · 201421 citationsRCR 1.2
- Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma.Bone Marrow Transplant · 200417 citationsRCR 0.4
- A Prospective, Randomized Trial Examining the Use of G-CSF Versus No G-CSF in Patients Post-Autologous Transplantation.Transplant Cell Ther · 20228 citationsRCR 0.6
- T cell repertoire complexity is conserved after LLME treatment of donor lymphocyte infusions.Biol Blood Marrow Transplant · 20076 citationsRCR 0.1